Partnership aims to develop efficacious and well-tolerated treatments for advanced metastatic breas...
* Regor announced its 12-week single-dose Phase 2a trial results for RGT-075, a once-daily oral G...
* Genentech will acquire Regor's next-generation CDK inhibitors for an upfront payment of$850 mil...
CAMBRIDGE, Mass., June 5, 2024 /PRNewswire/ -- Regor Therapeutics Group, a clinical-stage global b...
CAMBRIDGE, Mass., March 8, 2024 /PRNewswire/ -- Regor Therapeutics Group ("Regor"), a clinical-stag...
* RGT-419B, a next generation CDK4 inhibitor, was safe and well tolerated in a First-in-Human Phas...